US 12,168,693 B2
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
Hans Van Eenennaam, Nijmegen (NL); and Andrea Van Elsas, Oss (NL)
Assigned to ADURO BIOTECH HOLDINGS, EUROPE B.V., Oss (NL)
Filed by ADURO BIOTECH HOLDINGS, EUROPE B.V., Oss (NL)
Filed on Jan. 16, 2019, as Appl. No. 16/249,404.
Application 16/249,404 is a division of application No. 15/007,345, filed on Jan. 27, 2016, abandoned.
Application 15/007,345 is a continuation in part of application No. PCT/NL2014/050543, filed on Aug. 2, 2014.
Claims priority of application No. 2011262 (NL), filed on Aug. 2, 2013; and application No. 2012361 (NL), filed on Mar. 4, 2014.
Prior Publication US 2019/0135933 A1, May 9, 2019
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); A61K 2039/507 (2013.01); C07K 2317/75 (2013.01)] 5 Claims
 
1. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an anti-human CD27 agonistic antibody and an immune checkpoint inhibitor which is an anti-LAG-3 antibody,
wherein said anti-human CD27 agonistic antibody is chosen from:
an anti-human CD27 agonistic antibody comprising:
a) a heavy chain comprising a heavy chain CDR1 comprising the sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the sequence of SEQ ID NO: 3, and
b) a light chain comprising a light chain CDR1 comprising the sequence of SEQ ID NO: 4, a light chain CDR2 comprising the sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the sequence of SEQ ID NO: 6;
a humanized analogue of antibody hCD27.15; or
antibody 1F5,
wherein said anti-LAG3 antibody comprises a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NO: 23 and SEQ ID NO: 24, respectively,
wherein said anti-LAG-3 antibody is not a multispecific antibody that comprises additional immune checkpoint inhibitor components, and
wherein said method does not comprise administering to the subject a therapeutically effective amount of an anti-PD-L1 antibody or an additional immune checkpoint inhibitor.